FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254384198> ?p ?o ?g. }

• W4254384198 abstract "Great advances in neurodegenerative disease, cell and gene therapy have been made in recent decades. Following the recent advancement of stem cell-based neuronal therapies, including managing their differentiation potential, research on cell sources for brain cell replacement methods has gained major importance. The objective is to obtain a certain neuronal cell fate to repair and restore the injured cell function. Several cell-based therapeutic techniques that show promise in animal HD models have failed to attain a similar degree of success in human patients. Despite its poor prospects, fetal transplantation has opened the door to a potentially intriguing new domain of regenerative medicine. However, many obstacles need to be overcome before pre-differentiated stem cells can be used in clinical trials, and, in particular, ensuring that the source of stem cells has optimal differentiation potential with full integration and functional enhancement, has measurable clinical benefits with minimal impact on the host immune system, and is tumor-free. New cell, molecular, and pharmacological approaches may assist enhance neuronal survival of transplanted cells, and consequently therapy for many fatal brain diseases. Molecular approaches, on the other hand, have looked into the idea of entirely eliminating HTT utilizing RNAi in the hopes of preventing the mutant protein that produced it in the first place. In contrast, HTT's physiological significance requires the application of procedures that specifically interfere with MHTHTT. The CRISPR/Cas9 approach gives researchers the ability to inactivate the mHTT allele by deleting or editing particular regions, leading to increased knowledge of how to prevent mutation-induced toxicity. Overall, despite their appealing ability to reverse mHTT-induced toxicity, these therapies may face difficulties due to the need to modify their design for individuals in order to ensure therapeutic safety.As clinical investigations are planned, genome editing already shows promise as a potent treatment to overcome clinical HD features. While there is no certainty that HD symptomatology can be fully eased, researchers must continue to hunt for ways to diminish it because it has such profound and life-threatening effects on patients and their families. These new treatments are supposed to bring a brighter future for HD sufferers." @default.
• W4254384198 created "2022-05-12" @default.
• W4254384198 creator A5016938750 @default.
• W4254384198 date "2021-06-12" @default.
• W4254384198 modified "2023-10-01" @default.
• W4254384198 title "Research on cell sources for brain cell replacement methods has gained major importance. Cell and gene therapy are potentially intriguing new domains of regenerative medicine" @default.
• W4254384198 doi "https://doi.org/10.31219/osf.io/g835b" @default.
• W4254384198 hasPublicationYear "2021" @default.
• W4254384198 type Work @default.
• W4254384198 citedByCount "0" @default.
• W4254384198 crossrefType "posted-content" @default.
• W4254384198 hasAuthorship W4254384198A5016938750 @default.
• W4254384198 hasConcept C104317684 @default.
• W4254384198 hasConcept C10854531 @default.
• W4254384198 hasConcept C10882517 @default.
• W4254384198 hasConcept C111599444 @default.
• W4254384198 hasConcept C141071460 @default.
• W4254384198 hasConcept C144501496 @default.
• W4254384198 hasConcept C148738053 @default.
• W4254384198 hasConcept C1491633281 @default.
• W4254384198 hasConcept C169760540 @default.
• W4254384198 hasConcept C28328180 @default.
• W4254384198 hasConcept C2911091166 @default.
• W4254384198 hasConcept C54355233 @default.
• W4254384198 hasConcept C60644358 @default.
• W4254384198 hasConcept C70721500 @default.
• W4254384198 hasConcept C71924100 @default.
• W4254384198 hasConcept C86803240 @default.
• W4254384198 hasConcept C98108389 @default.
• W4254384198 hasConceptScore W4254384198C104317684 @default.
• W4254384198 hasConceptScore W4254384198C10854531 @default.
• W4254384198 hasConceptScore W4254384198C10882517 @default.
• W4254384198 hasConceptScore W4254384198C111599444 @default.
• W4254384198 hasConceptScore W4254384198C141071460 @default.
• W4254384198 hasConceptScore W4254384198C144501496 @default.
• W4254384198 hasConceptScore W4254384198C148738053 @default.
• W4254384198 hasConceptScore W4254384198C1491633281 @default.
• W4254384198 hasConceptScore W4254384198C169760540 @default.
• W4254384198 hasConceptScore W4254384198C28328180 @default.
• W4254384198 hasConceptScore W4254384198C2911091166 @default.
• W4254384198 hasConceptScore W4254384198C54355233 @default.
• W4254384198 hasConceptScore W4254384198C60644358 @default.
• W4254384198 hasConceptScore W4254384198C70721500 @default.
• W4254384198 hasConceptScore W4254384198C71924100 @default.
• W4254384198 hasConceptScore W4254384198C86803240 @default.
• W4254384198 hasConceptScore W4254384198C98108389 @default.
• W4254384198 hasLocation W42543841981 @default.
• W4254384198 hasOpenAccess W4254384198 @default.
• W4254384198 hasPrimaryLocation W42543841981 @default.
• W4254384198 hasRelatedWork W2607005583 @default.
• W4254384198 hasRelatedWork W2607137613 @default.
• W4254384198 hasRelatedWork W2615451290 @default.
• W4254384198 hasRelatedWork W2746918533 @default.
• W4254384198 hasRelatedWork W2796376989 @default.
• W4254384198 hasRelatedWork W2907672812 @default.
• W4254384198 hasRelatedWork W2942420995 @default.
• W4254384198 hasRelatedWork W2951941429 @default.
• W4254384198 hasRelatedWork W3000873784 @default.
• W4254384198 hasRelatedWork W3098367454 @default.
• W4254384198 isParatext "false" @default.
• W4254384198 isRetracted "false" @default.
• W4254384198 workType "article" @default.